Medical Marijuana Inc (OTCMKTS:MJNA) Just Made A Major Announcement And Nobody Noticed

Medical Marijuana Inc (OTCMKTS:MJNA) is down around 10% this week, and the company is down around 35% year to date. It's struggled to maintain the positive sentiment that it picked up in the wake of the cannabis legalization rush during the final quarter of last year, and despite having put out numerous developmental releases over the last couple of months relating to both its own and Axim Biotechnologies Inc (OTCMKTS:AXIM)'s (a company in which Medical Marijuana holds a substantial stake) operational activity, it's struggling to pick up any momentum.We think markets just missed a trick, and that we could soon see some strength from the stock.Here’s why.On March 17, Medical Marijuana announced that one of its subsidiaries, a company called HempMeds Mexico, garnered national news headlines across Mexico based on the results of a study investigating the effects of one of its products in treating children with severe epilepsy. Markets barely flinched when the news hit press.The product in question is called RDHO-X, and it's a type of hemp oil that contains CBD, but not TCH. For those not familiar with this sort of thing, THC is the psychoactive compound in cannabis. CBD also activates receptors in the endocannabinoid system, but focused more no the CNS, meaning it doesn’t have any psychoactive effect on a user (in other words, it's not going to get users high).The data from the recent study detailed the fact that 84% of children with epilepsy that were treated with RSHO-X halved the number of seizures they suffer from. Most of the children studied had a rare, nasty (and practically untreatable) form of epilepsy called Lennox-Gastaut.OK, so why is this a big deal?Well, the drug seems to help kids with a really serious condition, and that's great, but there's more than that. Take a look at this LA Times article form way back in 2012. It's about a boy who has Dravet's, which is similar to Lennox-Gastaut in that it’s a rare and severe form of epilepsy. Basically, his father found that the only thing that helped him was CBD oil, and the article goes on to discuss how he found it increasingly difficult to find said oil. The key point is that CBD oil helped like cannabis would, but the kid didn’t get high.Now, it's this concept (and there's speculation that it was specifically this kid) that inspired the now billion dollar biotech GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) to go after rare epilepsy (including Dravet's) with Epidiolex, and we all know how that turned out.With RDHO-X, Medical Marijuana is basically doing the exact same thing in South America that GW did in the US, and the latest data – the data that the Mexican press is all over, but that US press (and the wider markets) seem to have ignored – proves that it works.We already knew it worked, because GW Pharma has built a billion-dollar company off of this one concept. But now we know that Medical Marijuana's asset is equivalent, and that – just as importantly – it's helping kids in Mexico that have basically failed every other therapy regimen.This isn’t a market the size of the US, of course. And there's a long way to go before this will hit shelves with a pharmaceutical label, or be prescribed (on label) by physicians in South America. With that said, it's the only product of its type that has been accepted for import, and even as an over the counter pseudo-pharmaceutical product, with the right traction behind it and a combination of anecdotal and physician backed studies (the latter of which the company announced, and the former of which the media coverage should facilitate) there's a market for it.We will be updating our subscribers as soon as we know more. For the latest updates on MJNA, sign up below!Disclosure: We have no position in any of the securities mentioned and have not been compensated for this article.